Diamyd Technology Advances with US $ 1.84 Million Grant
Diamyd Inc, Pittsburgh, PA, USA, a wholly-owned subsidiary of Diamyd Medical, Stockholm Sweden, announces today that the United States Department of Veterans Affairs (VA) has awarded a $1.84 million grant to support the development of Diamyd’s Nerve Targeting Drug Delivery System (NTDDS) for Diabetic Neuropathic Pain.The two-year grant largely funds the advancement of NTDDS with Glutamic Acid Decarboxylase (GAD) through preclinical efficacy, toxicology and biodistribution studies, manufacturing and filing of an Investigational New Drug (IND) application with the Food and Drug Administration